yes i take peptides · shopping companion

Cagrilintide

Category · For Weight LossStatus · RUOCitations · 60

The verdict

A long-acting amylin analog. Mostly studied as a stack partner with semaglutide. The combo (CagriSema) hit roughly 22.7% weight loss in phase 3 — Wall Street viewed it as a disappointment vs Novo's pre-guidance.

By source — cost, legality, risk

Brand
Not available
None — not FDA-approved as monotherapy; CagriSema under review
No FDA-approved cagrilintide exists yet.
Compounded 503A pharmacy
$200–$500/mo where available
Off-label compounding · not on FDA bulks list, legally contested
Mid–high. Compounders shipping cagrilintide pre-approval are legally exposed.
RUO research peptide
$80–$150/mo
Sold 'for research only'
Highest. The dominant pre-approval supply path. No purity guarantee.
Gray-market raw
$22–$25/mo
Unregulated overseas import
Crypto/Wise pay; pre-approval molecule so identity verification is hard — no reference standards yet.

Sources · top 5 of 60

01Garvey WT, et al. Coadministered Cagrilintide and Semaglutide in Adults with Overweight or Obesity. The New England journal of medicine. 2025;393(7):635-647. PMID: 40544433.
02Davies MJ, et al. Cagrilintide-Semaglutide in Adults with Overweight or Obesity and Type 2 Diabetes. The New England journal of medicine. 2025;393(7):648-659. PMID: 40544432.
03Lau DCW, et al. Once-weekly cagrilintide for weight management in people with overweight and obesity: a multicentre, randomised, double-blind, placebo-controlled and active-controlled, dose-finding phase 2 trial. Lancet (London, England). 2021;398(10317):2160-2172. PMID: 34798060.
04Frias JP, et al. Efficacy and safety of co-administered once-weekly cagrilintide 2·4 mg with once-weekly semaglutide 2·4 mg in type 2 diabetes: a multicentre, randomised, double-blind, active-controlled, phase 2 trial. Lancet (London, England). 2023;402(10403):720-730. PMID: 37364590.
05Dutta D, et al. Efficacy and Safety of Cagrilintide Alone and in Combination with Semaglutide (Cagrisema) as Anti-Obesity Medications: A Systematic Review and Meta-Analysis. Indian journal of endocrinology and metabolism. 2024;28(5):436-444. PMID: 39676787.